Sanofi India Q1 FY27 Results (NSE: SANOFI)
Signal: Margin expansion
The read
Sanofi India delivered strong profit growth (+20.1% YoY) on 7.7% revenue increase, driven by domestic market leadership in diabetes and disciplined cost management; QoQ revenue decline is seasonal, but PBT margin expansion to 27% signals improving quality.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹437.7 Cr | +7.7% | -7.3% |
| EBIT | ₹112.6 Cr | +19.2% | |
| Net profit | ₹83.5 Cr | +20.1% | |
| EPS | ₹36.26 | +20.1% | |
| EBIT margin | 25.7% |
P&L walk
Profit growth outpaced revenue on favorable product mix and disciplined cost management, with operating expenses declining 5% and PBT margin expanding to 27%.
Key positives
- Diabetes portfolio grew 14% YoY for second consecutive quarter, reinforcing leadership in basal analog with 58% value market share.
- PBT margin improved to 27% from 24% YoY (as reported) through favorable product mix and 5% decline in operating expenses.
- Public sector business accelerated 70% with new accounts for Toujeo and Soliqua under CARE initiative.
- Strong net cash position of ₹3,590 million supports financial flexibility.
Key concerns
- Revenue declined 7.3% QoQ, indicating seasonality or lumpy order pattern.
- Export sales broadly flat, limiting growth diversification.
- Partnership revenues grew only 2%, suggesting limited near-term impact from strategic collaborations.
- Gross margin flat YoY, relying on cost control rather than pricing power in core portfolio.
Research and educational content only. Not investment advice.